CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-01 | Jackson Scott Thomas Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-05-01 | JUNIUS DANIEL M Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-03-29 | JUNIUS DANIEL M Director | Grant or award | +5,209 | $3.00 | $16K | 98,459 |
| 2024-03-29 | Goldberg Mark Alan Director | Grant or award | +4,584 | $3.00 | $14K | 24,828 |
| 2024-03-29 | King Rachel K. Director | Grant or award | +3,334 | $3.00 | $10K | 515,194 |
| 2024-01-12 | Johnson Bruce S SVP & Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-01-12 | Semerjian Harout Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +695,000 | 695,000 | ||
| 2024-01-12 | Rock Edwin Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-01-12 | Rath Chinmaya SVP and Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-01-12 | Hahn Brian M. SVP Finance, CFO | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2023-12-29 | Andrews Patricia S Director | Grant or award | +5,191 | $2.36 | $12K | 58,608 |
| 2023-12-29 | King Rachel K. Director | Grant or award | +4,238 | $2.36 | $10K | 511,860 |
| 2023-12-29 | Goldberg Mark Alan Director | Grant or award | +5,827 | $2.36 | $14K | 20,244 |
| 2023-09-30 | Goldberg Mark Alan Director | Grant or award | +9,167 | $1.50 | $14K | 14,417 |
| 2023-09-30 | Andrews Patricia S Director | Grant or award | +8,167 | $1.50 | $12K | 53,417 |
| 2023-09-30 | King Rachel K. Director | Grant or award | +6,667 | $1.50 | $10K | 507,622 |
| 2023-09-22 | Rock Edwin Chief Medical Officer | Purchase | +30,403 | $1.38 | $42K | 375,403 |
| 2023-09-21 | Rock Edwin Chief Medical Officer | Purchase | +35,000 | $1.38 | $48K | 345,000 |
| 2023-06-01 | Koenig Scott Director | Option exercise | +21,000 | $0.60 | $13K | 36,750 |
| 2023-06-01 | Koenig Scott Director | Option exercise · Stock option (right to buy) | −21,000 | 0 |
Page 5 of 16 · 305 trades